Complementation of two mutant p53: Implications for loss of heterozygosity in cancer

FEBS Letters

Volumn 579, Issue 10, 2005, Pages 2231-2235

  Demidenko, Zoya N ^a   Fojo, Tito ^b   Blagosklonny, Mikhail V ^a,c  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

Cancer; p53; Tumor suppressor

Indexed keywords

MUTANT PROTEIN; PROTEIN P53;

ALLELE; ARTICLE; CANCER CELL; CONTROLLED STUDY; DNA BINDING; GENE DELETION; GENE MUTATION; GENETIC COMPLEMENTATION; GENETIC TRANSFECTION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION;

EID: 16344388755     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2005.03.012     Document Type: Article

References (42)

1. B. Vogelstein, D. Lane, and A.J. Levine Surfing the p53 network Nature 408 2000 307 310
2. B. Vogelstein, and K.W. Kinzler Cancer genes and the pathways they control Nat. Med. 10 2004 789 799
3. S.J. Baker, A.C. Preisinger, J.M. Jessup, C. Paraskeva, S. Markowitz, J.K. Willson, S. Hamilton, and B. Vogelstein p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis Cancer Res. 50 1990 7717 7722
4. Y. Haupt, A.I. Robles, C. Prives, and V. Rotter Deconstruction of p53 functions and regulation Oncogene 21 2002 8223 8231
5. J.K. Sax, and W.S. El-Deiry p53 downstream targets and chemosensitivity Cell Death Differ. 10 2003 413 417
6. T. Fojo p53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53 Drug Resistance Update 5 2002 209 216
7. C.L. Brooks, and W. Gu Dynamics in the p53-Mdm2 ubiquitination pathway Cell Cycle 3 2004 895 899
8. Y. Haupt, R. Maya, A. Kazaz, and M. Oren Mdm2 promotes the rapid degradation of p53 Nature 387 1997 296 299
9. M.H. Kubbutat, S.N. Jones, and K.H. Vousden Regulation of p53 stability by Mdm2 Nature 387 1997 299 303
10. P. Giannakakou, G. Poy, Z. Zhan, T. Knutsen, M.V. Blagosklonny, and T. Fojo Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer Oncogene 19 2000 3078 3085
11. M.V. Blagosklonny p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect FASEB J. 14 2000 1901 1907
12. M.V. Blagosklonny, P. Giannakakou, L.Y. Romanova, K.M. Ryan, K.H. Vousden, and T. Fojo Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions Carcinogenesis 22 2001 861 867
13. C.A. Midgley, and D.P. Lane p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding Oncogene 15 1997 1179 1189
14. C.D. Nicholls, K.G. McLure, M.A. Shields, and P.W. Lee Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect J. Biol. Chem. 277 2002 12937 12945
15. Y. Sun, Z. Dong, K. Nakamura, and N.H. Colburn Dosage-dependent dominance over wild-type p53 of a mutant p53 isolated from nasopharyngeal carcinoma FASEB J. 7 1993 944 950
16. T. Frebourg, M. Sadelain, Y.S. Ng, J. Kassel, and S.H. Friend Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype Cancer Res. 54 1994 878 881
17. P. Davis, K. Bazar, G. Huper, G. Lozano, J. Marks, and J.D. Iglehart Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells Oncogene 13 1996 1315 1322
18. M.V. Blagosklonny, and W.S. el-Deiry In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug Int. J. Cancer 67 1996 386 392
19. S.N. Rodin, and A.S. Rodin Human lung cancer and p53: the interplay between mutagenesis and selection Proc. Natl. Acad. Sci. USA 97 2000 12244 12249
20. G. Blandino, A.J. Levine, and M. Oren Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy Oncogene 18 1999 477 485
21. A. Lanyi, D. Deb, R.C. Seymour, J.H. Ludes-Meyers, M.A. Subler, and S. Deb 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain Oncogene 16 1998 3169 3176
22. L. Weisz, A. Zalcenstein, P. Stambolsky, Y. Cohen, N. Goldfinger, M. Oren, and V. Rotter Transactivation of the EGR1 gene contributes to mutant p53 gain of function Cancer Res. 64 2004 8318 8327
23. A. Zalcenstein Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants Oncogene 22 2003 5667 5676
24. T.J. O'Farrell, P. Ghosh, N. Dobashi, C.Y. Sasaki, and D.L. Longo Comparison of the effect of mutant and wild-type p53 on global gene expression Cancer Res. 64 2004 8199 8207
25. A. Sigal, and V. Rotter Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome Cancer Res. 60 2000 6788 6793
26. M.V. Blagosklonny, J. Toretskey, and L.M. Neckers Geldanamycin selectively destabilizes and conformationally alters mutated p53 Oncogene 11 1995 933 939
27. K.V. Gurova, O.W. Rokhlin, A.V. Budanov, L.G. Burdelya, P.M. Chumakov, M.B. Cohen, and A.V. Gudkov Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells Cancer Res. 63 2003 2905 2912
28. K.G. McLure, and P.W. Lee How p53 binds DNA as a tetramer EMBO J. 17 1998 3342 3350
29. P. Chene The role of tetramerization in p53 function Oncogene 20 2001 2611 2617
30. W. Zhang, J.W. Shay, and A. Deisseroth Inactive p53 mutants may enhance the transcriptional activity of wild-type p53 Cancer Res. 53 1993 4772 4775
31. Y. Nagata The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association Oncogene 18 1999 6037 6049
32. G. Selivanova, T. Kawasaki, L. Ryabchenko, and K.G. Wiman Reactivation of mutant p53: a new strategy for cancer therapy Semin. Cancer Biol. 8 1998 369 378
33. R. Takimoto, W. Wang, D.T. Dicker, F. Rastinejad, J. Lyssikatos, and W.S. El-Deiry CP-31398 restores sequence-specific DNA binding ability to p53 and induces p21WAF1 gene expression in mutant p53-expressing SW480 human colon cancer cells Cancer Biol. Ther 2002
34. T.M. Rippin, V.J. Bykov, S.M. Freund, G. Selivanova, K.G. Wiman, and A.R. Fersht Characterization of the p53-rescue drug CP-31398 in vitro and in living cells Oncogene 21 2002 2119 2129
35. A.L. Kim, A.J. Raffo, P.W. Brandt-Rauf, M.R. Pincus, R. Monaco, P. Abarzua, and R.L. Fine Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells J. Biol. Chem. 274 1999 34924 34931
36. B.A. Foster, H.A. Coffey, M.J. Morin, and F. Rastinejad Pharmacological rescue of mutant p53 conformation and function Science 286 1999 2507 2510
37. J. Milner, and E.A. Medcalf Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation Cell 65 1991 765 774
38. M.V. Blagosklonny, W.G. An, L.Y. Romanova, J. Trepel, T. Fojo, and L. Neckers p53 inhibits hypoxia inducible factor-stimulated transcription J. Biol. Chem. 273 1998 11995 11998
39. W.S. El-Deiry WAF1, a potential mediator of p53 tumor suppression Cell 75 1993 817 825
40. Y. Haupt, S. Rowan, E. Shaulian, K.H. Vousden, and M. Oren Induction of apoptosis in HeLa cells by trans-activation-deficient p53 Genes Dev. 9 1995 2170 2183
41. M.S. Soengas Inactivation of the apoptosis effector Apaf-1 in malignant melanoma Nature 409 2001 207 211
42. M.V. Blagosklonny Paradox of Bcl-2 (and p53): why may apoptosis-regulating proteins be irrelevant to cell death? Bioessays 23 2001 947 953